296 related articles for article (PubMed ID: 32727536)
1. PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.
Noorani I; de la Rosa J; Choi YH; Strong A; Ponstingl H; Vijayabaskar MS; Lee J; Lee E; Richard-Londt A; Friedrich M; Furlanetto F; Fuente R; Banerjee R; Yang F; Law F; Watts C; Rad R; Vassiliou G; Kim JK; Santarius T; Brandner S; Bradley A
Genome Biol; 2020 Jul; 21(1):181. PubMed ID: 32727536
[TBL] [Abstract][Full Text] [Related]
2. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice.
Holland EC; Hively WP; DePinho RA; Varmus HE
Genes Dev; 1998 Dec; 12(23):3675-85. PubMed ID: 9851974
[TBL] [Abstract][Full Text] [Related]
3. Genetic modeling of gliomas in mice: new tools to tackle old problems.
Hambardzumyan D; Parada LF; Holland EC; Charest A
Glia; 2011 Aug; 59(8):1155-68. PubMed ID: 21305617
[TBL] [Abstract][Full Text] [Related]
4. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
[TBL] [Abstract][Full Text] [Related]
5. Characterizing temporal genomic heterogeneity in pediatric high-grade gliomas.
Salloum R; McConechy MK; Mikael LG; Fuller C; Drissi R; DeWire M; Nikbakht H; De Jay N; Yang X; Boue D; Chow LML; Finlay JL; Gayden T; Karamchandani J; Hummel TR; Olshefski R; Osorio DS; Stevenson C; Kleinman CL; Majewski J; Fouladi M; Jabado N
Acta Neuropathol Commun; 2017 Oct; 5(1):78. PubMed ID: 29084603
[TBL] [Abstract][Full Text] [Related]
6. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
7. Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality.
Collier LS; Adams DJ; Hackett CS; Bendzick LE; Akagi K; Davies MN; Diers MD; Rodriguez FJ; Bender AM; Tieu C; Matise I; Dupuy AJ; Copeland NG; Jenkins NA; Hodgson JG; Weiss WA; Jenkins RB; Largaespada DA
Cancer Res; 2009 Nov; 69(21):8429-37. PubMed ID: 19843846
[TBL] [Abstract][Full Text] [Related]
8. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas.
Gömöri E; Pál J; Kovács B; Dóczi T
Diagn Pathol; 2012 Jan; 7():8. PubMed ID: 22264301
[TBL] [Abstract][Full Text] [Related]
9. Mutant IDH1 Promotes Glioma Formation In Vivo.
Philip B; Yu DX; Silvis MR; Shin CH; Robinson JP; Robinson GL; Welker AE; Angel SN; Tripp SR; Sonnen JA; VanBrocklin MW; Gibbons RJ; Looper RE; Colman H; Holmen SL
Cell Rep; 2018 May; 23(5):1553-1564. PubMed ID: 29719265
[TBL] [Abstract][Full Text] [Related]
10. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
11. In vivo functional characterization of EGFR variants identifies novel drivers of glioblastoma.
Yu K; Kong K; Lozzi B; Luna-Figueroa E; Cervantes A; Curry R; Mohila CA; Rao G; Jalali A; Mills GB; Scott KL; Deneen B
Neuro Oncol; 2023 Mar; 25(3):471-481. PubMed ID: 36044040
[TBL] [Abstract][Full Text] [Related]
12. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.
Chen R; Cohen AL; Colman H
Curr Treat Options Oncol; 2016 Aug; 17(8):42. PubMed ID: 27334978
[TBL] [Abstract][Full Text] [Related]
14. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
[TBL] [Abstract][Full Text] [Related]
15. Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.
Golding SE; Morgan RN; Adams BR; Hawkins AJ; Povirk LF; Valerie K
Cancer Biol Ther; 2009 Apr; 8(8):730-8. PubMed ID: 19252415
[TBL] [Abstract][Full Text] [Related]
16. Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations.
Sa JK; Choi SW; Zhao J; Lee Y; Zhang J; Kong DS; Choi JW; Seol HJ; Lee JI; Iavarone A; Rabadan R; Nam DH
Int J Cancer; 2019 Jun; 144(12):3023-3030. PubMed ID: 30536544
[TBL] [Abstract][Full Text] [Related]
17. Comparative Molecular Life History of Spontaneous Canine and Human Gliomas.
Amin SB; Anderson KJ; Boudreau CE; Martinez-Ledesma E; Kocakavuk E; Johnson KC; Barthel FP; Varn FS; Kassab C; Ling X; Kim H; Barter M; Lau CC; Ngan CY; Chapman M; Koehler JW; Long JP; Miller AD; Miller CR; Porter BF; Rissi DR; Mazcko C; LeBlanc AK; Dickinson PJ; Packer RA; Taylor AR; Rossmeisl JH; Woolard KD; Heimberger AB; Levine JM; Verhaak RGW
Cancer Cell; 2020 Feb; 37(2):243-257.e7. PubMed ID: 32049048
[TBL] [Abstract][Full Text] [Related]
18. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA.
Sun Y; Zhang W; Chen D; Lv Y; Zheng J; Lilljebjörn H; Ran L; Bao Z; Soneson C; Sjögren HO; Salford LG; Ji J; French PJ; Fioretos T; Jiang T; Fan X
Proc Natl Acad Sci U S A; 2014 Mar; 111(9):3538-43. PubMed ID: 24550449
[TBL] [Abstract][Full Text] [Related]
19. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
[TBL] [Abstract][Full Text] [Related]
20. Correction to: PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas.
Noorani I; de la Rosa J; Choi YH; Strong A; Ponstingl H; Vijayabaskar MS; Lee J; Lee E; Richard-Londt A; Friedrich M; Furlanetto F; Fuente R; Banerjee R; Yang F; Law F; Watts C; Rad R; Vassiliou G; Kim JK; Santarius T; Brandner S; Bradley A
Genome Biol; 2020 Aug; 21(1):206. PubMed ID: 32799926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
